Plaintiffs' Attorneys Representing Talc-Cancer Victims Form Ad Hoc Committee to Support J&J Settlement

Leadership committee seeks to bring resolution to decade-long legal battle

Lawyers representing approximately 55,000 plaintiffs in the litigation against Johnson & Johnson (NYSE: JNJ) over its cancer-causing talcum powder products have formed an Ad Hoc Committee to support an $8.9 billion deal that would end a decade-long legal battle against the pharmaceutical giant.

To view the ad hoc statement, click here .

J&J subsidiary, LTL Management, filed Chapter 11 bankruptcy a second time to resolve claims by establishing an $8.9 billion trust to compensate cancer victims. Once approved, J&J has committed to paying all current claimants within one year and removing all talc-based products from store shelves worldwide.

"These victims and their families have waited long enough for fair compensation," said trial lawyer Majed Nachawati , founding partner of Dallas -based Nachawati Law Group. "Although no amount of money can replace what these families have lost, we are proud to be a part of ad hoc leadership to resolve this litigation and finally bring some sense of peace to our clients."

The Ad Hoc Committee has retained Paul Hastings , Cole Schotz , and Parkins & Rubio LLP as co-bankruptcy counsel. The Ad Hoc Committee is comprised of attorneys from Nachawati Law Group; OnderLaw, LLC; Watts Guerra LLP; Wisner Baum ; Pulaski Kherkher , PLLC; Ferrer, Poirot, Wansbrough; Feller & Daniel; Rueb, Stoller & Daniel, LLP; Linville Law Group; Slater Slater Schulman LLP; Johnson Law Group; McDonald Worley ; Trammell PC; Andres Pereira Law Firm; and Jenn Liakos Law .

Seventy-five percent of claimants must vote to approve the settlement. The Ad Hoc Committee is believed to hold a supermajority of talc claims against J&J.

Scientific studies linked J&J products to serious illnesses and cancers more than a decade ago. An investigation into J&J's own records revealed that not only did the company know of the dangers and risks associated with its products, including the iconic Baby Powder, but it also hid those facts from unsuspecting consumers for years. The initial bankruptcy ploy, in which the company dumped jury verdicts from thousands of cancer lawsuits into a shell company before filing for Chapter 11 protection, was rejected by the Third Circuit Court of Appeals.

Nachawati Law Group represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation.

For more information visit https://ntrial.com/

Media Contact:
Alyssa Woulfe
800-559-4534
alyssa@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/plaintiffs-attorneys-representing-talc-cancer-victims-form-ad-hoc-committee-to-support-jj-settlement-301804295.html

SOURCE Nachawati Law Group

News Provided by PR Newswire via QuoteMedia

JNJ
The Conversation (0)
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global... Keep Reading...
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition,... Keep Reading...
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at... Keep Reading...

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). As quoted in the press release: The collaboration will explore the potential for Kaleido’s... Keep Reading...

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech. As quoted in the press release: Upon closing, Janssen paid XBiotech $750 million, with $75 million held in escrow for 18 months. Should Janssen pursue... Keep Reading...
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News